Currently, IL-1β blockade with the human monoclonal antibody (mAb) canakinumab is being tested in a Phase II clinical trial for the treatment of low or intermediate risk MDS and CML (NTC04239157). This evidence concerns the gene IL1B and myelodysplastic syndrome.